RU2015134772A - Применение биматопроста для повышения выработки лептина - Google Patents
Применение биматопроста для повышения выработки лептина Download PDFInfo
- Publication number
- RU2015134772A RU2015134772A RU2015134772A RU2015134772A RU2015134772A RU 2015134772 A RU2015134772 A RU 2015134772A RU 2015134772 A RU2015134772 A RU 2015134772A RU 2015134772 A RU2015134772 A RU 2015134772A RU 2015134772 A RU2015134772 A RU 2015134772A
- Authority
- RU
- Russia
- Prior art keywords
- bimatoprost
- administered
- leptin
- production
- preadipocytes
- Prior art date
Links
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title claims 13
- 229960002470 bimatoprost Drugs 0.000 title claims 13
- 238000000034 method Methods 0.000 claims 26
- 102000016267 Leptin Human genes 0.000 claims 3
- 108010092277 Leptin Proteins 0.000 claims 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 3
- 229940039781 leptin Drugs 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 210000000229 preadipocyte Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793132P | 2013-03-15 | 2013-03-15 | |
| US61/793,132 | 2013-03-15 | ||
| PCT/US2014/026110 WO2014143629A1 (en) | 2013-03-15 | 2014-03-13 | Bimatoprost for enhancement of leptin production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015134772A true RU2015134772A (ru) | 2017-04-21 |
| RU2015134772A3 RU2015134772A3 (cg-RX-API-DMAC7.html) | 2018-03-21 |
Family
ID=50442712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015134772A RU2015134772A (ru) | 2013-03-15 | 2014-03-13 | Применение биматопроста для повышения выработки лептина |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140275272A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968361A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016513647A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150129735A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105338985A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014228307A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015021859A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2901529A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1220385A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015134772A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014143629A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3721885A1 (en) | 2015-04-30 | 2020-10-14 | Allergan, Inc. | Cosmetic method and therapeutic use for fat reduction |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DE69212850T2 (de) | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| CA2681668C (en) * | 2006-03-23 | 2014-04-01 | Michael S. Singer | Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat |
| EP2398443A2 (en) * | 2009-02-20 | 2011-12-28 | Micro Labs Limited | Storage stable prostaglandin product |
| CA2866067C (en) * | 2011-01-19 | 2015-04-21 | Topokine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
-
2014
- 2014-03-13 JP JP2016502054A patent/JP2016513647A/ja active Pending
- 2014-03-13 KR KR1020157025059A patent/KR20150129735A/ko not_active Withdrawn
- 2014-03-13 HK HK16108521.3A patent/HK1220385A1/zh unknown
- 2014-03-13 WO PCT/US2014/026110 patent/WO2014143629A1/en not_active Ceased
- 2014-03-13 US US14/209,099 patent/US20140275272A1/en not_active Abandoned
- 2014-03-13 EP EP14716168.1A patent/EP2968361A1/en not_active Withdrawn
- 2014-03-13 AU AU2014228307A patent/AU2014228307A1/en not_active Abandoned
- 2014-03-13 CN CN201480012846.5A patent/CN105338985A/zh active Pending
- 2014-03-13 BR BR112015021859A patent/BR112015021859A2/pt active Search and Examination
- 2014-03-13 CA CA2901529A patent/CA2901529A1/en not_active Abandoned
- 2014-03-13 RU RU2015134772A patent/RU2015134772A/ru not_active Application Discontinuation
-
2015
- 2015-11-25 US US14/952,208 patent/US20160310505A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105338985A (zh) | 2016-02-17 |
| HK1220385A1 (zh) | 2017-05-05 |
| AU2014228307A1 (en) | 2015-09-10 |
| JP2016513647A (ja) | 2016-05-16 |
| CA2901529A1 (en) | 2014-09-18 |
| US20140275272A1 (en) | 2014-09-18 |
| EP2968361A1 (en) | 2016-01-20 |
| WO2014143629A1 (en) | 2014-09-18 |
| KR20150129735A (ko) | 2015-11-20 |
| BR112015021859A2 (pt) | 2017-07-18 |
| RU2015134772A3 (cg-RX-API-DMAC7.html) | 2018-03-21 |
| US20160310505A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| CN102670928B (zh) | 一种治疗颈椎病及腰椎病的膏药 | |
| JP2017501154A5 (cg-RX-API-DMAC7.html) | ||
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| TN2015000480A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| JP2011520902A5 (cg-RX-API-DMAC7.html) | ||
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| RU2015134772A (ru) | Применение биматопроста для повышения выработки лептина | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| So et al. | Effect of compression bandaging on wound healing and psychosocial outcomes in older people with venous ulcers: a randomized controlled trial | |
| CN201542976U (zh) | 一种具有穴位治疗作用的新型黑膏药 | |
| CL2018003268A1 (es) | Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel. | |
| JP2016513647A5 (cg-RX-API-DMAC7.html) | ||
| CN112972440B (zh) | 麝香酮在制备防治抑郁症的药物中的用途 | |
| MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
| Gimmelreich et al. | Sequential contraction compression devices reduce leg circumference in patients with chronic venous insufficiency | |
| CN104208433A (zh) | 一种治疗手足癣的中药制剂 | |
| CN103251805A (zh) | 一种治疗皮肤病的外用药物组合物 | |
| Wang et al. | ASSA14-10-01 Haemodynamic effects of short-term infusion of recombinant human atrial natriuretic peptide (rhANP) for acute decompensated heart failure: a randomised, double-blind, placebo-controlled, multicenter study | |
| Shuixiang | ASSA14-10-02 Treatment Effect of Trimetazidin on Cardiac Function in Mild-Moderate Systolic Heart Failure Patients with Coronary Heart Disease | |
| RU2019145090A (ru) | Комбинированный биологический препарат для лечения эндометритов у сельскохозяйственных животных | |
| Bäcker et al. | Psychophysiological response to acupuncture—Impact of stimulus intensity and personality | |
| Morales | Bradycardia and hypotension: case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180731 |